The medical technology industry is facing a hiring reality that leaders can no longer ignore: regulatory affairs talent has become one of the hardest roles to fill—and one of the most critical.

Across the global MedTech sector, companies are racing to launch innovative devices, expand into new markets, navigate shifting compliance rules, and respond to evolving U.S. Food and Drug Administration (FDA) expectations. At the center of all of it sits one function: Regulatory Affairs.

Once viewed primarily as a back-office compliance team, Regulatory Affairs is now a strategic growth engine. For many MedTech firms in 2026, hiring the right regulatory professional can mean the difference between hitting launch targets or losing a year of revenue. 

Why Demand Has Surged

Several forces have collided at once, creating what many in the industry are calling a talent squeeze.

1. FDA Resource Constraints Are Increasing Complexity

Industry observers report that FDA device review teams, particularly within the Center for Devices and Radiological Health (CDRH), have faced staffing strain and workload pressure. That means companies must submit cleaner, faster, and more strategic filings than ever before. Weak submissions are more likely to trigger delays, additional information requests, or missed timelines. 

This has elevated the value of experienced professionals who know how to manage:

• 510(k) submissions
• De Novo requests
• PMA applications
• Pre-submission meetings
• Labeling strategy
• Risk management documentation
• Global technical files

In short: companies need experts who can get approvals right the first time.

2. Faster Innovation Means More Regulatory Work

MedTech innovation is accelerating across:

• AI-enabled diagnostics
• Connected devices
• Remote monitoring systems
• Robotics
• Digital therapeutics
• Combination products

Each new category introduces regulatory questions around software validation, cybersecurity, clinical evidence, post-market monitoring, and changing guidance expectations. IQVIA notes that AI adoption and digital health expansion are major forces shaping MedTech in 2026. 

Innovation creates opportunity—but also paperwork, risk, and scrutiny.

3. Global Expansion Requires Multi-Market Expertise

Today’s growth-stage MedTech companies are no longer satisfied with one-market launches. They want simultaneous or near-simultaneous access to:

United States
European Union
Canada
Japan
Australia
Brazil

That requires professionals who understand FDA pathways and MDR, IVDR, Health Canada, PMDA, TGA, and ANVISA requirements.

Those people are rare—and expensive.

Why Regulatory Affairs Is No Longer Just Compliance

The strongest MedTech companies now bring Regulatory Affairs into business decisions early.

Modern RA leaders influence:

• Product design decisions
• Clinical strategy
• Launch sequencing
• Label claims
• Market expansion plans
• Reimbursement timing
• M&A due diligence
• Quality system readiness

Recent coordination between FDA and CMS to speed Medicare coverage decisions for certain breakthrough devices shows how regulatory strategy increasingly connects directly to commercialization and revenue timelines. 

That is why many CEOs now treat RA hires as revenue-enabling hires, not overhead hires.

The Most In-Demand Regulatory Profiles in 2026

Hiring demand is especially strong for professionals with experience in:

Senior Regulatory Affairs Managers / Directors

Leaders who can build submission strategy, manage teams, and communicate with regulators.

Global Regulatory Specialists

Professionals who understand both FDA and international frameworks.

Software / SaMD Regulatory Experts

High demand due to AI and connected device growth.

Quality + Regulatory Hybrids

Candidates who understand both compliance systems and submissions are highly valuable.

Interim / Fractional Regulatory Consultants

Companies unable to hire full-time are increasingly using contract talent to hit milestones quickly.

Why Hiring Is So Difficult

The supply problem is real.

Experienced regulatory professionals are difficult to replace because success depends on years of hands-on judgment—not just textbook knowledge. Employers increasingly want candidates who have managed real submissions, agency questions, labeling changes, and product-specific filings. 

That means companies are competing for a relatively small pool of proven operators.

What Smart MedTech Companies Are Doing Now

Winning companies are adapting by:

Hiring Earlier

They recruit RA talent 6–12 months before major submissions.

Offering Remote Roles

Top candidates expect flexibility.

Using Specialized Recruiters

Generic hiring methods often fail for niche regulatory roles.

Building Talent Pipelines

Strong firms develop junior RA professionals internally while hiring senior leaders externally.

Treating RA as Strategic Leadership

The best candidates want influence, not just document ownership.

What This Means for 44 International

For global MedTech organizations, the message is clear: regulatory hiring is no longer optional backfill—it is strategic infrastructure.

At 44 International, we see firsthand that companies who secure top Regulatory Affairs talent move faster, reduce approval risk, and outperform slower competitors.

In today’s market, waiting to hire regulatory professionals until “later” often becomes the most expensive delay of all.

Final Thought

Every MedTech executive wants innovation.

But innovation without regulatory execution is just an idea in a prototype lab.

Right now, the most valuable hire in MedTech may not be in engineering, sales, or operations.

It may be the Regulatory Affairs professional who knows how to get your product to market.